Protective Effect of Nasal Drops in COVID Infection

Protective Efficacy of Anu Taila Nasya in Healthcare Professionals against SARS-CoV-2 (COVID-19) Infection: A Double Blind Placebo Controlled Clinical Trial - NASALSHIELD

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/06/034061

Enrollment

400

Registered

2021-06-07

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Anu Taila: Application of TWO Drops of the medicated oil in each nostril twice a day for 28 days Control Intervention1: Tila Taila: Application of TWO Drops of the oil in each nostril t

Eligibility

Inclusion criteria

Inclusion criteria: 1. Individuals 20-60 years of age. 2. Healthy 3. The participant must have normal hemogram, 4. No systemic disease, 5. Agree not to self-medicate with other potential antivirals during the course of the study. 6. The participant must have the ability to use the product as directed 7. Participant must have the willingness 8. Participant must have ability to understand the nature of trial and the follow-up procedures.

Exclusion criteria

Exclusion criteria: 1. History of COVID-19 infection within 90 days 2. History of helminthic infection, 3. History of diabetes or any other systemic disease 4. Individuals who are symptomatic or convalescent. 5. Individuals who are on other prophylactic/s 6. Individuals who do not have the ability and willingness to use the product.

Design outcomes

Primary

Measure	Time frame
Decrease in Viral LoadTimepoint: 28 days	—

Secondary

Measure	Time frame
Free from disease If infected, they will have mild symptomsTimepoint: 3 Months	—

Countries

India

Contacts

Public ContactAnandaraman Sharma PV

Artemis Hospitals

namita@artemishospitals.com9716822224

Outcome results